IDEXX LABORATORIES INC /DE — Director's Dealing 2015

Feb 18, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2015-02-14

Reporting Person: MCKEON BRIAN P (Executive VP, CFO & Treasurer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-02-14	Common Stock	M	363	—	Acquired	14562	Direct
2015-02-14	Common Stock	F	117	$159.08	Disposed	14445	Direct
2015-02-17	Common Stock	M	5000	$29.27	Acquired	19445	Direct
2015-02-17	Common Stock	S	2000	$156.4366	Disposed	17445	Direct
2015-02-17	Common Stock	S	3000	$157.3627	Disposed	14445	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-02-14	Non-Qualified Stock Option (right to buy)	$159.08	A	18108	Acquired	2025-02-13	Common Stock (18108)	Direct
2015-02-14	Incentive Stock Option (right to buy)	$159.08	A	628	Acquired	2025-02-13	Common Stock (628)	Direct
2015-02-14	Restricted Stock Unit	$	A	1572	Acquired		Common Stock (1572)	Direct
2015-02-14	Restricted Stock Unit	$	M	363	Disposed		Common Stock (363)	Direct
2015-02-17	Non-Qualified Stock Option (right to buy)	$29.27	M	5000	Disposed	2015-05-17	Common Stock (5000)	Direct

Footnotes

F1: The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/20/2014.

F2: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $155.91 to $156.84, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.

F3: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $156.91 to $157.90, inclusive.

F4: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that becomes exercisable as to 3,748 shares on 02/14/2016, 3,747 shares on 02/14/2017, 02/14/2018 and 02/14/2019, and the remaining 3,119 shares on 02/14/2020.

F5: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests on the fifth anniversary date (02/14/2020) of the grant.

F6: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2016) of the date of grant.

F7: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vested in five equal annual installments, beginning on the first anniversary date (02/14/2015) of the date of grant.

F8: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested fully on 05/10/2006.